https://www.yiliao.com/index.php?action=history&feed=atom&title=%E9%9D%B6%E5%90%91%E8%8D%AF%E7%89%A9%E5%8C%B9%E9%85%8D
靶向药物匹配 - 版本历史
2026-04-19T12:39:09Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E9%9D%B6%E5%90%91%E8%8D%AF%E7%89%A9%E5%8C%B9%E9%85%8D&diff=313919&oldid=prev
221.219.184.196：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-10T10:56:11Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[靶向药物匹配]] (Targeted Therapy Matching)</strong> 是 <strong>[[精准肿瘤学]]</strong> 的核心临床环节。它通过 <strong>[[二代测序 (NGS)]]</strong>、<strong>[[免疫组化 (IHC)]]</strong> 或 <strong>[[FISH]]</strong> 等检测手段，识别患者肿瘤中特定的驱动基因突变、融合或蛋白过表达，并将其与已被证实的有效药物进行逻辑关联。这种“以变异为向导”的策略旨在打破传统化疗的“盲目性”，显著提升客观缓解率（ORR）并延长无进展生存期（PFS）。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 380px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.25em; font-weight: bold; letter-spacing: 1.2px;">药物匹配档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Precision Matching · 2026 版</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 10px; font-weight: 600;">核心任务：分子靶点与药物精准匹配</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.82em;"><br />
<tr style="background-color: #f1f5f9; color: #1e40af; font-weight: bold; text-align: center;"><br />
<td colspan="2" style="padding: 6px; border-bottom: 1px solid #e2e8f0;">匹配技术支柱</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9; width: 40%;">检测金标准</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">[[二代测序 (NGS)]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9;">辅助手段</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">IHC, FISH, PCR</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9;">临床依据</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">伴随诊断 (CDx) 指南</td><br />
</tr><br />
<tr style="background-color: #f1f5f9; color: #1e40af; font-weight: bold; text-align: center;"><br />
<td colspan="2" style="padding: 6px; border-bottom: 1px solid #e2e8f0;">匹配效能参数</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9;">证据等级</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">ESCAT 证据分级</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9;">匹配结果</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">敏感、耐药、临床意义不明</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc;">动态匹配</th><br />
<td style="padding: 6px 10px; color: #e11d48;">[[液体活检]] 耐药监测</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">常见癌种的经典匹配方案</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
随着药物研发的爆发式增长，目前的匹配已经涵盖了绝大多数实体瘤及血液系统恶性肿瘤：<br />
</p><br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">癌种</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">关键匹配靶点</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">代表性药物 (2026 示例)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">非小细胞肺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">EGFR 突变 (19del/L858R), ALK/ROS1 融合, KRAS G12C。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[奥希替尼]], 洛拉替尼, 索托拉西布。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">乳腺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">HER2 扩增/突变, ER/PR 阳性, BRCA1/2 突变。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">[[德曲妥珠单抗 (DS-8201)]], 帕妥珠单抗, 奥拉帕利。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">结直肠癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">KRAS/NRAS 野生型, BRAF V600E, HER2 阳性。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">西妥昔单抗, 维莫非尼, 曲妥珠单抗。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">黑色素瘤</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">BRAF V600 突变, KIT 突变。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">达拉非尼+曲美替尼, 伊马替尼。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">不限癌种 (Tissue-Agnostic) 的“广谱”匹配</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
2026 年的治疗趋势日益倾向于“同病异治”与“异病同治”的结合。如果发现以下靶点，无论癌症起源于哪个器官，均可匹配特定药物：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[NTRK 融合]]：</strong> 匹配拉罗替尼 (Larotrectinib) 或恩曲替尼，对几十种不同器官的肿瘤展现出极高有效率。</li><br />
<li style="margin-bottom: 12px;"><strong>[[MSI-H / dMMR]]：</strong> 匹配 PD-1 抑制剂，这是首个基于分子特征而非癌种获批的匹配模式。</li><br />
<li style="margin-bottom: 12px;"><strong>[[TMB-H]]：</strong> 高肿瘤突变负荷患者通常可匹配免疫治疗。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">权威参考文献与专家点评</h2><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 15px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Abdollahi, S., et al. (2025).</strong> <em>Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions.</em> <strong>Journal of Personalized Medicine</strong>, 15(4).<br><br />
<span style="color: #475569;">[专家点评]：详述了 NGS 在识别治疗靶点和监测耐药演化中的关键角色，是精准匹配的最新指南。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>NCCN Clinical Practice Guidelines in Oncology. (2026).</strong> <em>Biomarker Testing in Solid Tumors.</em><br><br />
<span style="color: #475569;">[专家点评]：动态更新的匹配标准，规定了哪些突变必须通过伴随诊断（CDx）来匹配对应药物以获得报销及合规性。</span><br />
</p><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[伴随诊断]] (Companion Diagnostics, CDx)：</strong> 随药物一同获批的特定检测试剂，用于筛选最适匹配人群。</li><br />
<li style="margin-bottom: 8px;"><strong>[[液体活检]]：</strong> 在治疗过程中通过血液监测耐药突变（如 EGFR T790M/C797S），实现“动态二次匹配”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[抗体偶联药物 (ADC)]]：</strong> 2026 年的高速增长领域，如 HER2 靶向的 ADC 彻底改变了“HER2 低表达”人群的匹配规则。</li><br />
</ul><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
靶向药物匹配 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 110px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">驱动激酶轴</td><br />
<td style="padding: 10px 15px; color: #334155;">[[RTK 激活]]•[[RAS-RAF-MEK-ERK 通路]]•[[PI3K-AKT-mTOR 通路]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 110px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">匹配逻辑</td><br />
<td style="padding: 10px 15px; color: #334155;">[[驱动突变识别]]•[[药物基因组学]]•[[耐药谱图分析]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 110px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">匹配深度</td><br />
<td style="padding: 10px 15px; color: #334155;">[[一线标准治疗]]•[[后线抢救匹配]]•[[临床试验入组匹配]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
221.219.184.196